Your browser doesn't support javascript.
loading
Meningococcus serogroup C clonal complex ST-10217 outbreak in Zamfara State, Northern Nigeria.
Kwambana-Adams, Brenda A; Amaza, Rahab C; Okoi, Catherine; Rabiu, Murtala; Worwui, Archibald; Foster-Nyarko, Ebenezer; Ebruke, Bernard; Sesay, Abdul K; Senghore, Madikay; Umar, Abdullahi S; Usman, Rabi; Atiku, Adamu; Abdullahi, Garba; Buhari, Yahaya; Sani, Rabiu; Bako, Husaini U; Abdullahi, Bashir; Yarima, Alliyu I; Sikiru, Badaru; Moses, Aderinola Olaolu; Popoola, Michael O; Ekeng, Eme; Olayinka, Adebola; Mba, Nwando; Kankia, Adamu; Mamadu, Ibrahim N; Okudo, Ifeanyi; Stephen, Mary; Ronveaux, Olivier; Busuttil, Jason; Mwenda, Jason M; Abdulaziz, Mohammed; Gummi, Sulaiman A; Adedeji, Adebayo; Bita, Andre; Omar, Linda; Djingarey, Mamoudou Harouna; Alemu, Wondimagegnehu; D'Alessandro, Umberto; Ihekweazu, Chikwe; Antonio, Martin.
Affiliation
  • Kwambana-Adams BA; World Health Organization, Collaborating Centre for New Vaccines Surveillance, Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine, Atlantic Boulevard, Fajara, PO Box 273, Banjul, The Gambia.
  • Amaza RC; Nigeria Center for Disease Control, Abuja, Nigeria.
  • Okoi C; World Health Organization, Collaborating Centre for New Vaccines Surveillance, Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine, Atlantic Boulevard, Fajara, PO Box 273, Banjul, The Gambia.
  • Rabiu M; Ahmad Sani Yariman Bakura Specialist Hospital Gusau, Zamfara State, Gusau, Nigeria.
  • Worwui A; World Health Organization, Collaborating Centre for New Vaccines Surveillance, Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine, Atlantic Boulevard, Fajara, PO Box 273, Banjul, The Gambia.
  • Foster-Nyarko E; World Health Organization, Collaborating Centre for New Vaccines Surveillance, Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine, Atlantic Boulevard, Fajara, PO Box 273, Banjul, The Gambia.
  • Ebruke B; World Health Organization, Collaborating Centre for New Vaccines Surveillance, Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine, Atlantic Boulevard, Fajara, PO Box 273, Banjul, The Gambia.
  • Sesay AK; World Health Organization, Collaborating Centre for New Vaccines Surveillance, Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine, Atlantic Boulevard, Fajara, PO Box 273, Banjul, The Gambia.
  • Senghore M; World Health Organization, Collaborating Centre for New Vaccines Surveillance, Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine, Atlantic Boulevard, Fajara, PO Box 273, Banjul, The Gambia.
  • Umar AS; Zamfara State Ministry of Health, Gusau, Nigeria.
  • Usman R; Zamfara State Ministry of Health, Gusau, Nigeria.
  • Atiku A; Zamfara State Ministry of Health, Gusau, Nigeria.
  • Abdullahi G; Nigeria Center for Disease Control, Abuja, Nigeria.
  • Buhari Y; Ahmad Sani Yariman Bakura Specialist Hospital Gusau, Zamfara State, Gusau, Nigeria.
  • Sani R; Ahmad Sani Yariman Bakura Specialist Hospital Gusau, Zamfara State, Gusau, Nigeria.
  • Bako HU; Ahmad Sani Yariman Bakura Specialist Hospital Gusau, Zamfara State, Gusau, Nigeria.
  • Abdullahi B; Ahmad Sani Yariman Bakura Specialist Hospital Gusau, Zamfara State, Gusau, Nigeria.
  • Yarima AI; Ahmad Sani Yariman Bakura Specialist Hospital Gusau, Zamfara State, Gusau, Nigeria.
  • Sikiru B; Nigeria Center for Disease Control, Abuja, Nigeria.
  • Moses AO; Nigeria Center for Disease Control, Abuja, Nigeria.
  • Popoola MO; Nigeria Center for Disease Control, Abuja, Nigeria.
  • Ekeng E; Nigeria Center for Disease Control, Abuja, Nigeria.
  • Olayinka A; Nigeria Center for Disease Control, Abuja, Nigeria.
  • Mba N; Nigeria Center for Disease Control, Abuja, Nigeria.
  • Kankia A; World Health Organization, Country Office Nigeria, Abuja, Nigeria.
  • Mamadu IN; World Health Organization, Country Office Nigeria, Abuja, Nigeria.
  • Okudo I; World Health Organization, Country Office Nigeria, Abuja, Nigeria.
  • Stephen M; World Health Organization, Country Office Nigeria, Abuja, Nigeria.
  • Ronveaux O; World Health Organization, Geneva, Switzerland.
  • Busuttil J; UK-Public Health Rapid Support Team, Public Health England, Salisbury, UK.
  • Mwenda JM; World Health Organization, Regional office for Africa, Brazzaville, Congo.
  • Abdulaziz M; Africa Centres for Diseases Control and Prevention, Addis Ababa, Ethiopia.
  • Gummi SA; Zamfara State Ministry of Health, Gusau, Nigeria.
  • Adedeji A; Nigeria Center for Disease Control, Abuja, Nigeria.
  • Bita A; World Health Organization Inter-Country Support Teams for West Africa, Ouagadougou, Burkina Faso.
  • Omar L; World Health Organization, Regional office for Africa, Brazzaville, Congo.
  • Djingarey MH; World Health Organization, Regional office for Africa, Brazzaville, Congo.
  • Alemu W; World Health Organization, Country Office Nigeria, Abuja, Nigeria.
  • D'Alessandro U; Disease Control and Elimination Theme, Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine, Atlantic Boulevard, Fajara, PO Box 273, Banjul, The Gambia.
  • Ihekweazu C; Nigeria Center for Disease Control, Abuja, Nigeria.
  • Antonio M; World Health Organization, Collaborating Centre for New Vaccines Surveillance, Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine, Atlantic Boulevard, Fajara, PO Box 273, Banjul, The Gambia. mantonio@mrc.gm.
Sci Rep ; 8(1): 14194, 2018 09 21.
Article in En | MEDLINE | ID: mdl-30242204
ABSTRACT
After the successful roll out of MenAfriVac, Nigeria has experienced sequential meningitis outbreaks attributed to meningococcus serogroup C (NmC). Zamfara State in North-western Nigeria recently was at the epicentre of the largest NmC outbreak in the 21st Century with 7,140 suspected meningitis cases and 553 deaths reported between December 2016 and May 2017. The overall attack rate was 155 per 100,000 population and children 5-14 years accounted for 47% (3,369/7,140) of suspected cases. The case fatality rate (CFR) among children 5-9 years was 10%, double that reported among adults ≥ 30 years (5%). NmC and pneumococcus accounted for 94% (172/184) and 5% (9/184) of the laboratory-confirmed cases, respectively. The sequenced NmC belonged to the ST-10217 clonal complex (CC). All serotyped pneumococci were PCV10 serotypes. The emergence of NmC ST-10217 CC outbreaks threatens the public health gains made by MenAfriVac, which calls for an urgent strategic action against meningitis outbreaks.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neisseria meningitidis, Serogroup C / Meningitis, Meningococcal Type of study: Incidence_studies / Prognostic_studies Limits: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Country/Region as subject: Africa Language: En Journal: Sci Rep Year: 2018 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neisseria meningitidis, Serogroup C / Meningitis, Meningococcal Type of study: Incidence_studies / Prognostic_studies Limits: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Country/Region as subject: Africa Language: En Journal: Sci Rep Year: 2018 Document type: Article
...